39 completed, 3 terminated, 3 unknown, 1 active not recruiting. 15 Phase 3, 12 Phase 1, 9 Phase 2, 7 Phase 4, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 14, Unknown 1 |
| Phase 1 | 12 | Completed 11, Terminated 1 |
| Phase 2 | 9 | Completed 5, Terminated 3, Unknown 1 |
| Phase 4 | 7 | Completed 6, Unknown 1 |
| Not applicable | 3 | Completed 3 |
Follow ropinirole: new trials by email Literature Review of ropinirole trials Research Report on ropinirole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exercise Training Versus Ropinirole in Treating Restless Legs Syndrome Among Hemodialysis Patients Dopamine Agonist (Ropinirole), Excercise training - Hemodialysis, Restless Legs Syndrome | Not applicable | Completed | Lahore General Hospital | 84 | 2022-01-02 | 2024-06-21 |
| DIalysis Symptom COntrol-Restless Legs Syndrome Trial Gabapentin, Ropinirole, Placebo Gabapentin - End Stage Renal Disease, Restless Legs Syndrome | Phase 3 | Completed | Population Health Research Institute | 52 | 2019-05-01 | 2022-09-21 |
| Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD Ropinirole, Gabapentin, Placebos - Restless Legs Syndrome, End Stage Renal Disease | Phase 2 | Terminated | University of Alberta | 3 | 2019-02-19 | 2022-07-12 |
| Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole Ropinirole oral product, Ropinirole Implant - Parkinson Disease | Phase 1 / Phase 2 | Terminated | Titan Pharmaceuticals | 6 | 2017-10-10 | 2023-05-06 |
| Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Ropinirole - Hyperprolactinemia, Prolactinoma | Phase 1 / Phase 2 | Completed | Columbia University | 16 | 2016-09-16 | 2024-06-04 |
| Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis Vitamin E, Ropinirole, Muscle cramp survey - Muscle Cramp, Cirrhosis | Phase 4 | Completed | Vanderbilt University Medical Center | 31 | 2016-09-02 | 2022-10-31 |
| Gait Analysis in Neurological Disease Anti-Parkinson medication, Deep Brain Stimulation - Parkinson's Disease, Parkinsonian Disorders | Active not recruiting | Beth Israel Deaconess Medical Center | 120 | 2016-03-01 | 2026-07-08 | |
| Cognitive Remediation for Cocaine Dependence levodopa/carbidopa, Ropinirole 2 mg/d, Placebo - Cocaine Dependence | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 119 | 2011-06-01 | 2018-03-29 |
| Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects Ropinirole - Parkinson Disease | Phase 1 | Completed | GlaxoSmithKline | 24 | 2010-06-28 | 2018-06-19 |
| Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists piribedil, pramipexole or ropinirole - Idiopathic Parkinson's Disease | Phase 3 | Completed | Desitin Arzneimittel GmbH | 80 | 2010-01-01 | 2012-05-24 |
| Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration) Ropinirole immediate release (IR), Placebo - Restless Legs Syndrome | Phase 2 | Terminated | GlaxoSmithKline | 34 | 2009-11-30 | 2018-08-10 |
| Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fasting Condition Ropinirole - Healthy | Phase 1 | Completed | Dr. Reddy's Laboratories Limited | 48 | 2009-10-01 | 2012-09-28 |
| Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fed Condition Ropinirole - Healthy | Phase 1 | Completed | Dr. Reddy's Laboratories Limited | 48 | 2009-10-01 | 2012-09-28 |
| A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients SPM 962, Ropinirole, Placebo - Parkinson's Disease | Phase 3 | Completed | Otsuka Pharmaceutical Co., Ltd. | 420 | 2009-06-01 | 2014-05-23 |
| Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease ropinirole PR/XR, ropinirole IR - Parkinson Disease | Phase 3 | Completed | GlaxoSmithKline | 302 | 2009-03-01 | 2017-01-18 |
| Two Way Cross Over BE Fasting Pilot Study of Ropinirole Hydrochloride CR 2mg Tablets Test Product (Ropinirole), Reference Product (REQUIP ) - Pharmacokinetic Study | Phase 1 | Completed | Lupin Ltd. | 12 | 2008-09-01 | 2012-10-23 |
| Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fasting Conditions Ropinirole hydrochloride CR Tablets 2mg - Pharmacokinetic Study | Phase 1 | Completed | Lupin Ltd. | 12 | 2008-09-01 | 2012-10-30 |
| Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fed Conditions Ropinirole hydrochloride CR 2mg Tablets - Pharmacokinetic Study | Phase 1 | Completed | Lupin Ltd. | 12 | 2008-09-01 | 2012-10-26 |
| MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist Safinamide (as add-on therapy) - Idiopathic Parkinson's Disease | Phase 3 | Completed | Newron Pharmaceuticals SPA | 679 | 2007-11-01 | 2013-10-29 |
| Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type Ropinirole - Unverricht-Lundborg Syndrome | Phase 2 | Unknown | University of Turku | 16 | 2007-08-01 | 2008-03-19 |
Showing 20 of 46. Sign in to see all of them.
Parkinson Disease (17) · Restless Legs Syndrome (15) · Depression (3) · Bipolar Disorder (2) · Dyskinesias (2) · Kidney Failure, Chronic (2) · Parkinsonian Disorders (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cocaine-Related Disorders (1) · Corticobasal Degeneration (1) · Depressive Disorder, Major (1) · Diabetes Complications (1) · Ejaculatory Dysfunction (1) · Fatigue (1)
GlaxoSmithKline (15) · Lupin Ltd. (3) · Dr. Reddy's Laboratories Limited (2) · Roxane Laboratories (2) · Teva Pharmaceuticals USA (2) · Agarwal, Pinky, M.D. (1) · Axxonis Pharma AG (1) · Beth Israel Deaconess Medical Center (1) · Boehringer Ingelheim (1) · Cambridge Health Alliance (1) · Columbia University (1) · Desitin Arzneimittel GmbH (1) · Lahore General Hospital (1) · Newron Pharmaceuticals SPA (1) · Otsuka Pharmaceutical Co., Ltd. (1)
United States (20) · Germany (10) · India (6) · Italy (5) · Canada (4) · Czechia (4) · France (4) · South Africa (4) · Spain (4) · Belgium (3) · Finland (3) · Japan (3) · Poland (3) · Argentina (2) · Bulgaria (2)
Satyanarayana V, M.Pharma., Ph.D (3) · Dr. Naba Kr Talukdar, MD (2) · Richard Larouche, M.D. (2) · Andrew Scanga, MD (1) · David J. Hellerstein, MD (1) · Dr. Kate Beebe DeVarney (1) · Dr. Michael Walsh, PhD,FRCPC(C) (1) · Gabrielle Page-Wilson, M.D. (1) · Heike Benes, MD (1) · Jonathan Willmer, MD (1) · Kyoji Imaoka, Mr (1) · Leon Grunhaus, MD (1) · Martina Wangemann, Dr. (1)
PMID 19520987, PMID 23938061, PMID 28078162, PMID 33294203, PMID 34600245, PMID 37715962
R21DK112093 (1)